SCHEMBL19972911

SCHEMBL19972911

CN(OC(=O)C(=O)ON(C)c1cnccn1)c1cnccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.47
KDM4E B2RXH2 6/20 0.38
NAPRT Q6XQN6 1/20 0.38
HCAR2 Q8TDS4 1/20 0.38
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HTT P42858 2/20 0.38
TP53 P04637 1/20 0.38
GAA P10253 1/20 0.38
TRPM8 Q7Z2W7 1/20 0.38
TSHR P16473 2/20 0.37
ADORA3 P0DMS8 1/20 0.37
MC4R P32245 1/20 0.37
ADRA1A P35348 1/20 0.37
MC3R P41968 1/20 0.37
ALDH1A1 P00352 1/20 0.35
CYP1A2 P05177 1/20 0.35
RAB9A P51151 2/20 0.34
NPC1 O15118 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1933894 0.73 POLB (0.50) POLBKDM4ENAPRTHCAR2LMNA
SCHEMBL13627918 0.73 KDM4E (0.50) POLBKDM4ENAPRTHCAR2LMNA
SCHEMBL30227483 0.73 KDM4E (0.50) POLBKDM4ENAPRTHCAR2LMNA
SCHEMBL28519924 0.72 POLB (0.49) POLBKDM4ENAPRTHCAR2LMNA
Ampyzine SCHEMBL30627403 0.71
Ampyzine SCHEMBL160265 0.71
SCHEMBL13367380 0.71 POLB (0.55) POLBKDM4ENAPRTHCAR2LMNA
Ampyzine SCHEMBL122178 0.69 POLB (0.50) POLBKDM4ENAPRTHCAR2LMNA
SCHEMBL1265669 0.69 POLB (0.42) POLBKDM4ENAPRTHCAR2LMNA
SCHEMBL23070375 0.69 POLB (0.46) POLBKDM4ENAPRTHCAR2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114591223-B Beta-lactamase inhibitor compounds 恩塔西斯治疗有限公司 2025-01-24 CN disclosed
EP-3512851-B1 BETA-LACTAMASE INHIBITOR COMPOUNDS ENTASIS THERAPEUTICS LTD (GB) 2022-07-06 EP disclosed
CN-114591223-A Beta-lactamase inhibitor compounds 恩塔西斯治疗有限公司 2022-06-07 CN disclosed
CN-109715630-B Beta-lactamase inhibitor compounds 恩塔西斯治疗有限公司 2022-02-22 CN disclosed
US-10800778-B2 Beta-lactamase inhibitor compounds ENTASIS THERAPEUTICS LIMITED (GB) 2020-10-13 US disclosed
EP-3512851-A1 BETA-LACTAMASE INHIBITOR COMPOUNDS Entasis Therapeutics Limited (GB) 2019-07-24 EP disclosed
US-20190202832-A1 BETA-LACTAMASE INHIBITOR COMPOUNDS ENTASIS THERAPEUTICS LIMITED (GB) 2019-07-04 US disclosed
WO-2018053215-A1 BETA-LACTAMASE INHIBITOR COMPOUNDS ENTASIS THERAPEUTICS LIMITED (GB) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190202832-A1 BETA-LACTAMASE INHIBITOR COMPOUNDS LCT, MGAM, MRPL21 POLB 992/4885KDM4E 2131/4885NAPRT 1328/4885
US-10800778-B2 Beta-lactamase inhibitor compounds LCT, MGAM, MRPL21 POLB 992/4885KDM4E 2131/4885NAPRT 1328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.